 | |
- close
- close
|
PR Newswire
Oct 20
Comment
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals (Nasdaq: HEPH) has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on partnering Hollis-Eden's lead program Apoptone, currently in
PR Newswire
Sep 16
Comment
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced that it received a
MarketWatch
Jun 16
Comment
Shares of Genzyme Corp. fall on news that the company is temporarily halting drug production at a plant due to contamination, while Amgen climbs after an analyst upgrade.
MarketWatch
Jun 15
Comment
Drug stocks fall sharply with the broader market in afternoon trading as investors fret over talk this weekend that various member nations of the so-called G8 may move soon to end stimulus spending.
MarketWatch
Jun 15
Comment
Hollis-Eden Pharmaceuticals has appointed its interim chief executive officer, James Frincke, as CEO and president. Frincke, who has served as interim CEO since March, joined the company in 1997 as its vice president for research and development....
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
HEPH AT A GLANCE
References
| ||||||
|
|
